Second-line chemotherapy for hormone-refractory prostate cancer: Has the time come?

Clinical Prostate Cancer

Volumn 3, Issue 2, 2004, Pages 122-124

  Rosenberg, Jonathan E ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial design; Predictive factors; Salvage chemotherapy; Taxanes

Indexed keywords

ANTIANDROGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; HYDROCORTISONE; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; SURAMIN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG CHOICE; DYSPNEA; HORMONE REFRACTORY PROSTATE CANCER; HORMONE RESISTANCE; HUMAN; LUNG CANCER; MALE; METHODOLOGY; NAUSEA; NEUROPATHY; OVARY CANCER; PREDICTION; PROSTATE CANCER; REVIEW; SALVAGE CHEMOTHERAPY; SALVAGE THERAPY; SECOND LINE CHEMOTHERAPY;

EID: 6344284690     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.022     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts & Figures 2004. Atlanta, GA: ACS, 2004.
2. Ung JO, Richie JP, Chen MH, et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60:458-463.
3. Paquette EL, Sun L, Paquette LR, et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60:756-759.
4. Evans HS, Moller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 2003; 43:337-341.
5. Quaglia A, Vercelli M, Puppo A, et al. Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants. Eur J Cancer Prev 2003; 12:145-152.
6. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 2000; 23:381-390.
7. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149:607-609.
8. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997; 24:421-431.
9. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033.
10. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003; 62(suppl1):87-94.
11. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer results of the CALGB 9182 Study. J Clin Oncol 1999; 17:2506-2513.
12. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764.
13. Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168:2439-2443.
14. Eisenberger M, De Wit R, Berry W. A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 2004; 23:2 (Abstract #4).
15. Petrylak DP Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000; 27:24-29.
16. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer, recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
17. Petrylak D, Tangen C, Hussain M. SWOG 99-16: Randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednisone in men with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2004; 23:2 (Abstract #3).
18. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004; 171:1525-1528.
19. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 200; 19:2509-2516.
20. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16:3362-3368.
21. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88:130-135.
22. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5:26-35.
23. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6:1264-1270.
24. Gomes F, Marques A, Oliveira F. Docetaxel with estramustine in hormone-independent prostate cancer as second-line chemotherapy. Ann Oncol 2002; 13(supp5):95.
25. Goodin S, Rao KV, Engle EA, et al. A phase II study of docetaxel and vinorelbine in hormone refractory prostate cancer (HRPC) with and without prior chemotherapy. Proc Am Soc Clin Oncol 2002; 21:161b (Abstract #2459).
26. Small EJ, Apodaca D, Baron A. Second-line chemotherapy with doxorubicin/cyclophosphamide (DOX/CY) for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1997; 16:343a (Abstract #1227).
27. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-1237.
28. Smaletz O, Kelly WK, Horse-Grant D, et al. Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metasta-QC prostate cancer. Proc Am Soc Clin Oncol 2002; 21:184a (Abstract #732).
29. Kasimis B, Hwang SS, Chang VT, et al. Survival predictors in stage D3 prostate cancer in a cohort of VA patients. The role of PSA doubling time. Proc Am Soc Clin Oncol 2001; 20:184a (Abstract #732).
30. Nelson JB, Allen AR, Hulting SM, et al. Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression and survival. Proc Am Soc Clin Oncol 2004; 23:394 (Abstract #4554).
31. Kelland LR. An update on satraplatin: the first orally available platinum anti-cancer drug. Expert Opin Investig Drug 2000; 9:1373-1382.